INTRODUCTION
============

Cardiomyopathies are diseases of the myocardium. Classically, cardiomyopathies are divided into three categories on the basis of the phenotype of the diseased ventricles: hypertrophic, dilated or restrictive ([@b18-0050468]; [@b66-0050468]). Both hypertrophy and dilation of the ventricle can be beneficial initial adaptations to cardiac stress such as pressure or volume loading, but in cardiomyopathy such processes become excessive and maladaptive, causing ventricular dysfunction ([@b65-0050468]). There are numerous causes of cardiomyopathy, and more recent classifications of this disease focus on primary vs secondary cardiomyopathy, depending on whether the disease is restricted to the cardiac muscle ([@b66-0050468]; [@b34-0050468]). Single gene defects in sarcomeric or other cardiac muscle proteins are important causes of primary cardiomyopathy. Most of these gene defects cause hypertrophic forms of cardiomyopathy, but others can cause either hypertrophic or dilated cardiomyopathy, depending on genetic background or on the specific function of the protein that is affected by the mutation ([@b18-0050468]; [@b43-0050468]; [@b66-0050468]; [@b9-0050468]). For example, mutations in α-cardiac actin cause hypertrophic cardiomyopathy when they affect actin-myosin interaction (which generates the force of contraction), but cause dilated cardiomyopathy when they affect interactions between actin thin filaments and myocellular proteins outside the sarcomere (which generate transmission of force) ([@b42-0050468]). Other examples of single gene defects that can lead to dilated cardiomyopathy include mutations in α-tropomyosin ([@b43-0050468]), vinculin ([@b44-0050468]), sarcoglycan ([@b81-0050468]), desmin ([@b32-0050468]), titin ([@b20-0050468]) and actinin ([@b35-0050468]). All lead to impaired interaction between the sarcomere and the cytoskeleton. Interestingly, although myofibrils form connections to surrounding microtubules (MTs) and MTs are implicated in sarcomere development as well as in the regulation of mitosis and vesicular transport, we find no reports associating defects in the cardiac MT network with dilated cardiomyopathy ([@b14-0050468]).

CENP-F is a large multifunctional protein associated with the MT network. In the embryonic mouse, CENP-F protein expression is ubiquitous, although its expression is highest in the heart and brain ([@b22-0050468]). In a serial BrdU labeling assay of cardiac morphogenesis, high-level CENP-F expression was shown to be abruptly downregulated after neonatal day 6. This coincided precisely with cessation of myocyte cell division ([@b73-0050468]; [@b74-0050468]; [@b22-0050468]; [@b13-0050468]). Low levels of this gene product are detected in the adult heart. Although a causal relationship was not established, it is of interest that a recent screen of transcriptional profiling in human end-stage dilated cardiomyopathies identified CENP-F as being downregulated 2.3-fold compared with its expression in control hearts ([@b11-0050468]). This intriguing expression pattern, and its link with cardiac disease, argues strongly for studying the effects of a cardiac-specific deletion of the CENP-F protein.

The multiple functional roles for CENP-F also support this strategy. CENP-F is an MT-interacting protein, and was first described in cancer cell lines as a component of the outer kinetochore and as a binding partner of the retinoblastoma (Rb) protein ([@b60-0050468]; [@b33-0050468]; [@b87-0050468]). Several studies show that CENP-F stabilizes the attachment of MTs to the kinetochore in mitotic cells. Disruption of CENP-F in vitro causes mitotic delay, with failure of full kinetochore assembly and misalignment of chromosomes in a subset of cells during mitosis ([@b8-0050468]; [@b17-0050468]). Additionally, CENP-F binds and inhibits ATF-4, a transcription factor linked to cellular proliferation and differentiation ([@b86-0050468]). Although these and other in vitro studies link CENP-F to mitosis, disrupting CENP-F only delays but does not completely disrupt progression of mitosis ([@b2-0050468]; [@b17-0050468]; [@b16-0050468]). CENP-F interaction with Rb protein might be predicted to affect cell cycle progression; however, studies in murine embryonic stem (ES) cells and in avian myocyte lines suggest primary roles of this protein complex in differentiation instead ([@b47-0050468]; [@b61-0050468]). Thus, the role of CENP-F in mitosis is complex and, until now, all data implicating CENP-F in the regulation of cell proliferation has been through biochemical and in vitro studies.

Further studies have indicated broader functions for CENP-F and MTs beyond the limited role in mitosis. These include regulation of cell shape through interactions with the MT-binding protein NudE ([@b75-0050468]) and the centrosomal-binding protein Hook2 ([@b36-0050468]). Additionally, we have demonstrated that CENP-F directs protein trafficking through its interaction with syntaxin 4 and SNAP25, physically linking the MT network with transport vesicles ([@b54-0050468]; [@b55-0050468]). Specifically, using dye transfer studies, disruption of CENP-F function inhibits trafficking of connexins, resulting in loss of cell-cell coupling ([@b55-0050468]). Connexins, in particular connexin-43, are crucial for cell-cell transmission of the cardiac action potential ([@b21-0050468]; [@b67-0050468]).

Here we report the first in vivo disruption of *CENP-F* gene function. In these studies, we generated a mouse model utilizing the Cre-*loxP* system to ablate CENP-F protein expression in a cardiomyocyte-specific manner (termed *CENP-F^−/−^* hereafter). Although the overall structure of the *CENP-F^−/−^* heart was preserved, these hearts were smaller with completely consistent changes in morphogenesis, including decreased myocyte proliferation, thinner chamber walls and blunted ventricular trabeculation. In the adult, *CENP-F^−/−^* hearts had a significant reduction in the number of intercalated discs characterized by diminished accumulation of connexin-43 and interruption of myocyte-myocyte coupling. The MT network of *CENP-F^−/−^* myocytes, particularly costamere-associated tubules, was also disrupted. All of these defects are consistent with the reported functions of CENP-F. Importantly, these hearts invariably developed abnormal cardiac physiology, including progressive dilated cardiomyopathy with fibrosis, heart block and a pattern of gene expression consistent with this disease. Although it has long been postulated that the MT cytoskeleton plays a role in the development of heart disease, this is the first study to reveal a direct genetic link between disruption of an MT-associated protein and cardiomyopathy.

RESULTS
=======

CENP-F is successfully excised by cTNT-Cre to generate a cardiomyocyte-specific knockout
----------------------------------------------------------------------------------------

Attempts to create a globally targeted deletion of *CENP-F* resulted in ES cells with significant proliferative defects such that the lines could not be expanded (results not shown). This is consistent with results reported by others that CENP-F knockdown in pre-implantation bovine embryos arrest at the eight-cell stage ([@b79-0050468]). Therefore, we adopted a Cre-*loxP* approach to study *CENP-F* gene function on an outbred (CD-1) mouse background. Given the high expression of murine *CENP-F* in the developing heart ([Fig. 1A](#f1-0050468){ref-type="fig"}), mice with the first five exons of *CENP-F* flanked by *loxP* sites ([Fig. 1B](#f1-0050468){ref-type="fig"}) were crossed with a cardiac troponin T (cTNT)-Cre mouse to generate a cardiomyocyte-specific targeted deletion of *CENP-F*. The floxed region contains the functional binding domains for syntaxin 4, Hook2 and SNAP25 ([@b54-0050468]; [@b55-0050468]; [@b36-0050468]). Genotyping confirmed successful genomic incorporation of the 5′ *loxP* sites in *CENP-F^loxP/loxP^* mice (606 bp band) compared with wild type (WT; 572 bp band). The heterozygote exhibited both bands, as shown in [Fig. 1C](#f1-0050468){ref-type="fig"} (first three lanes).

![**Cardiomyocyte-specific disruption of the** ***CENP-F*** **gene.** (A) In situ hybridization of an E11.5 mouse embryo with an antisense *CENP-F* probe demonstrates the distribution of *CENP-F* transcripts. *CENP-F* is ubiquitous in the developing embryo but the highest levels of expression are observed in the heart (arrow) and regions of the brain. (B) A schematic presentation of the targeted *CENP-F* gene with the location of *loxP* sites marked by yellow arrowheads. Gray boxes indicate *CENP-F* exons. The first five exons of *CENP-F* are removed when crossed with the *cTNT-Cre* mouse line expressing Cre recombinase in cardiomyocytes beginning at E7.5. (C,D) Genomic PCR confirms Cre-mediated excision of the floxed *CENP-F* gene segment. Lanes are as labeled. In panel C, primers flank the 5′ *loxP* site and show different sized transcripts for WT and *loxP*-containing genes. In panel D, primers flank both *loxP* sites and amplify a product only when recombination has occurred (only in the heart). (E--H) CENP-F protein expression in WT (E,F) and *CENP-F^−/−^* (G,H) heart. Anti-CENP-F antibody staining is absent in *CENP-F^−/−^* cardiomyocytes, but retained in the overlying epicardium, where cTNT does not recombine (G,H; arrow).](DMM008680F1){#f1-0050468}

CENP-F ablation is specific to the heart in *cTNT-Cre;CENP-F^loxP/loxP^* mice (designated *CENP-F^−/−^* hereafter), as seen in PCR analysis with primers flanking the 5′ *loxP* site ([Fig. 1C,D](#f1-0050468){ref-type="fig"}). The remainder of [Fig. 1C](#f1-0050468){ref-type="fig"}, labeled 'tail' and 'heart', demonstrates the disappearance of the floxed band with the expression of Cre in the heart, whereas tail samples from the same mice show that the floxed allele remains intact. After Cre-mediated excision, a recombination band appears when primers flanking both *loxP* sites are used with the same DNA samples ([Fig. 1D](#f1-0050468){ref-type="fig"}).

Given that our targeting strategy generated a partial deletion of the *CENP-F* gene, it was important to verify that expression of CENP-F protein was ablated in the hearts of *CENP-F^−/−^* mice. [Fig. 1E--H](#f1-0050468){ref-type="fig"} demonstrates the difference in CENP-F protein expression when comparing 1-day-old (P1) WT and *CENP-F^−/−^* heart sections using an anti-CENP-F antibody. This antibody was generated against an epitope in exon 11, well downstream of the deleted sequence. In WT hearts, widespread CENP-F expression is observed throughout the myocardium ([Fig. 1E,F](#f1-0050468){ref-type="fig"}), whereas expression is absent in the myocardium of *CENP-F^−/−^* mice ([Fig. 1G,H](#f1-0050468){ref-type="fig"}). However, as an internal positive control, expression is visualized in the epicardium of the *CENP-F^−/−^* heart owing to the myocyte-specific nature of cTNT-Cre activity. Another commercially available antibody confirmed CENP-F ablation (data not shown). Taken together, these data demonstrate the cardiomyocyte-specific deletion of CENP-F.

*CENP-F^−/−^* hearts exhibit morphogenic abnormalities
------------------------------------------------------

Grossly, the heart structures of *CENP-F^−/−^* mice developed normally, including valves, endocardium and vessels. However, the ventricles of *CENP-F^−/−^* hearts were smaller and appeared distinctly more angular throughout embryonic life. This characteristic was observed in 100% of cases, and is shown in [Fig. 2A](#f2-0050468){ref-type="fig"}. Additionally, a modest reduction in the coronary vasculature and epicardial thickness in *CENP-F^−/−^* hearts was noted (data not shown). Postnatally, *CENP-F^−/−^* hearts continued to have less ventricular mass than controls; representative examples at P4 are shown in [Fig. 2B](#f2-0050468){ref-type="fig"}. At P4, the average heart weight for WT hearts was 10.05 mg, compared with 8.2 mg for *CENP-F^−/−^* hearts (18% difference; *P*≤0.02). The overall body size was not significantly different, although there was a trend for *CENP-F^−/−^* animals to be slightly smaller.

Histological examination of WT and *CENP-F^−/−^* hearts revealed that the atrial and ventricular walls on both left and right sides were invariably thinner in the *CENP-F^−/−^* heart at E12.5 and thereafter compared with controls ([Fig. 2C](#f2-0050468){ref-type="fig"} and supplementary material [Fig. S1A,B](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1)). Quantification of these data in the ventricular wall at E12.5 is given in [Fig. 2D](#f2-0050468){ref-type="fig"}. Additionally, clear differences in trabeculation of *CENP-F^−/−^* hearts were observed. These structures were thinner and blunted when compared with WT counterparts. These differences in heart wall thickness and trabeculation persisted throughout the embryonic period. On the CD-1 background, there was no apparent in utero loss of *CENP-F^−/−^* pups: WT, heterozygotes and *CENP-F^−/−^* mice were born in expected mendelian ratios (see supplementary material [Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1)). Thus, although loss of CENP-F function did not result in embryonic lethality and the structure of the heart was generally preserved, distinct and completely penetrant differences in wall morphogenesis and structure were consistently observed.

![**Embryonic and neonatal** ***CENP-F****^−/−^* **hearts display morphological differences in size and chamber wall thickness.** (A) Hearts from E12.5 WT and KO littermates. *CENP-F^−/−^* hearts have a distinctly angular appearance of the ventricle when compared with WT hearts. (B) Hearts from P4 mice. *CENP-F^−/−^* hearts are 30--40% smaller by weight than WT (*n*=12) yet no difference in animal size is observed. (C) Cross-sections through the widest point in the left ventricle show that the WT ventricle has thicker walls and is more trabeculated than the *CENP-F^−/−^* ventricle. The right ventricles of *CENP-F^−/−^* hearts were similarly affected (not shown). Arrows demonstrate regions where variation in wall thickness is readily observed. (D) Non-trabeculated regions of WT and *CENP-F^−/−^* ventricular wall were measured in μm (*n*=38). Significant differences in thickness were observed (*CENP-F^−/−^*: 28.8±4.8 μm; WT: 18.4±5.2 μm (mean ± s.d.; *P*\<0.05).](DMM008680F2){#f2-0050468}

*CENP-F^−/−^* hearts exhibit decreased proliferation in the prenatal and neonatal periods
-----------------------------------------------------------------------------------------

Overall wall thickness and trabeculation in *CENP-F^−/−^* hearts was attenuated. A possible explanation for this observation would be impaired cardiomyocyte proliferation. Because high-level CENP-F expression parallels the period of cardiomyocyte mitosis and CENP-F is thought to regulate cell proliferation in vitro, we examined the impact of CENP-F loss of function on myocyte proliferation. Prenatally, there is a threefold decrease in myocyte proliferation in *CENP-F^−/−^* hearts compared with WT (supplementary material [Fig. S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1)). Postnatally, we examined the pattern of BrdU incorporation daily over a period of 7 days. This corresponds to the time during which high-level CENP-F expression is downregulated and mitotic rates sharply decline ([@b13-0050468]). Compared with WT hearts, *CENP-F^−/−^* hearts had significantly lower levels of BrdU incorporation on P1-P4, but equal levels on P5-P7 ([Fig. 3](#f3-0050468){ref-type="fig"}). Phosphohistone H3 analysis of mitosis over this same timeframe confirmed the decrease in mitotic activity in the *CENP-F^−/−^* hearts ([Fig. 3](#f3-0050468){ref-type="fig"}). Analysis of apoptosis with TUNEL staining showed no significant difference between WT and knockout (KO) hearts (data not shown). These data suggest a positive effect of CENP-F on cardiomyocyte mitosis in the normal embryonic and neonatal heart, up until the time that high-level expression of CENP-F has been shown to decline. These results demonstrate that CENP-F disruption in the developing heart leads to decreased myocyte proliferation, reduced trabeculation, and a smaller and thin-walled heart. Thus, loss of CENP-F function consistently leads to reproducible changes in cardiac morphogenesis. With this information, we next determined whether the differentiated heart was susceptible to disease states.

![**BrdU and phosphohistone-H3 labeling of neonatal hearts demonstrates decreased proliferation in** ***CENP-F****^−/−^* **hearts.** (A--F) Cross-sections through WT (A--C) and *CENP-F^−/−^* (D--F) hearts showing anti-BrdU (green) with nuclear staining (DAPI, blue) after 90 minutes of in vivo BrdU labeling. Panels A and D show an overview of sections at neonatal day (N)4 at 10× magnification; others are days 2 and 4 as labeled at 20× magnification. Significantly fewer BrdU-positive cells are seen in the *CENP-F^−/−^* hearts. (G,H) Graphs showing the percentage of positive BrdU (G) and phosphohistone-H3 (H) labeling from P0-P7 in WT and *CENP-F^−/−^* hearts. All counts were performed on 40× sections; 6--16 fields are included for each data point. WT numbers are shown in blue/circles and *CENP-F^−/−^* in pink/squares. There is significantly less BrdU and phosphohistone-H3 labeling in the *CENP-F^−/−^* hearts until day 5, when WT and *CENP-F^−/−^* labeling equalizes for the remaining days assayed. \**P*≤0.001.](DMM008680F3){#f3-0050468}

Adult *CENP-F^−/−^* hearts have fewer intercalated discs
--------------------------------------------------------

CENP-F plays a central role in intracellular protein trafficking through its interaction with SNARE proteins ([@b55-0050468]). Specifically, movement of connexins to gap junctions is dependent on CENP-F activity ([@b55-0050468]). Because connexins are a crucial component of the intercalated disc and are required for regulation of electrical conduction between myocytes, we examined their presence at the disc using quantitative immunostaining (see Methods for protocol on disc quantification). In comparison to WT hearts ([Fig. 4A](#f4-0050468){ref-type="fig"}), *CENP-F^−/−^* hearts ([Fig. 4B](#f4-0050468){ref-type="fig"}) exhibited a 3.5-fold decrease in total intercalated disc number in the mature ventricle ([Fig. 4C](#f4-0050468){ref-type="fig"}; *P*≤0.001). Not only were differences in overall disc number observed, but connexin-43 staining in *CENP-F^−/−^* hearts was often punctate and not organized into a 'disc-like' structure. Additionally, the accumulation of Bves, a protein that is also enriched at the intercalated disc ([@b52-0050468]; [@b71-0050468]), was significantly diminished in *CENP-F^−/−^* hearts (supplementary material [Fig. S3E,F](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1)). N-cadherin accumulation at the cell surface and disc was also severely inhibited (supplementary material [Fig. S3A--D](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1)). These data indicate that loss of CENP-F function has a generalized effect on intercalated disc structure and function, and could directly relate to the conduction defects observed in electrocardiographic (ECG) analysis (see below).

*CENP-F^−/−^* myocytes have significant deficiencies in costamere structure
---------------------------------------------------------------------------

The costamere is essential for the transmission of mechanical force from the myofibril to the connective tissue matrix, and thus plays an important role in heart function ([@b49-0050468]; [@b48-0050468]; [@b1-0050468]). MTs are associated with these structures and are thought to play a role in stabilization of the myofibril and cell membrane ([@b57-0050468]). Because CENP-F is an MT-binding protein and is an important regulator of the MT network, we examined *CENP-F^−/−^* hearts for MT integrity. By confocal microscopy, we detected a qualitative decrease in the amount of tubulin accumulation in myocytes using an anti-tubulin antibody that detects all forms of the protein. These data are shown in [Fig. 5A--D](#f5-0050468){ref-type="fig"}. At higher power, examination of WT hearts with anti-tubulin antibodies revealed the characteristic ribbed pattern of MT staining, which is associated with costameres, perpendicular to the long axis of myofibrils (three consecutive sections of a confocal *z*-stack focused on the myocyte cell surface are given in [Fig. 5E--H](#f5-0050468){ref-type="fig"}). By contrast, confocal analysis through multiple sections determined that *CENP-F^−/−^* myocytes were completely devoid of this organized pattern of MT staining ([Fig. 5I--L](#f5-0050468){ref-type="fig"}). Taken together, these data demonstrate that costamere structure is severely impaired by loss of CENP-F function, and suggest that defects in cardiac contractility might be observed.

*CENP-F^−/−^* hearts develop dilated cardiomyopathy
---------------------------------------------------

Dilated cardiomyopathies have not been linked to MT dysfunction, but disruption of the costamere or intercalated disc has been associated with this disease ([@b52-0050468]; [@b1-0050468]; [@b57-0050468]; [@b19-0050468]). Because both of these structures are severely compromised by loss of CENP-F function, *CENP-F^−/−^* and WT littermates were serially analyzed for cardiac function from 4 to 26 weeks after birth. No differences in body weight or heart rate were detected between experimental and control groups. Serial conscious transthoracic echocardiography was performed at 1- to 4-week intervals. Typical M-mode images are shown in [Fig. 6A,B](#f6-0050468){ref-type="fig"}. The diastolic and systolic dimensions are as labeled with arrows (red, diastolic; yellow systolic). These data show decreasing left ventricular systolic function of *CENP-F^−/−^* mice with age ([Fig. 6D](#f6-0050468){ref-type="fig"}). The left ventricular posterior wall thickness was unaffected (not shown), whereas the left ventricular internal dimension in diastole was mildly increased ([Fig. 6C](#f6-0050468){ref-type="fig"}). Thus, *CENP-F^−/−^* mice developed a progressive form of dilated cardiomyopathy. These longitudinal studies showed full or 100% penetrance of this functional phenotype in the *CENP-F^−/−^* animal model.

![***CENP-F****^−/−^* **hearts contain fewer intercalated discs.** (A,B) Cross-section through WT (A) and *CENP-F^−/−^* (B) hearts at 12 months. Connexin-43 staining (green) shows a significant decrease in disc number in *CENP-F^−/−^* hearts as compared with WT. (C) Quantification of disc numbers shown as a fold increase. \**P*≤0.005.](DMM008680F4){#f4-0050468}

*CENP-F^−/−^* hearts develop arrhythmias
----------------------------------------

*CENP-F^−/−^* cardiomyocytes showed a marked decrease in the number of intercalated discs and a diminution in the accumulation of disc-related proteins. Thus, we assessed the conduction system of WT and *CENP-F^−/−^* hearts using continuous ECG recordings. These recordings were performed at 3 months of age, in the early stages of the cardiomyopathy detailed above. *CENP-F^−/−^* hearts displayed prolonged PR intervals, consistent with first degree heart block (data not shown). Furthermore, as shown in [Fig. 6E](#f6-0050468){ref-type="fig"}, there were rare instances of second degree heart block in *CENP-F^−/−^* animals; this was never observed in controls. More frequently, we observed sinus slowing, defined as P-P intervals greater than 200 ms, with 1:1 atrioventricular (AV) conduction, suggestive of sinus node dysfunction ([Fig. 6F](#f6-0050468){ref-type="fig"}). This finding was observed in 4/5 *CENP-F^−/−^* animals studied, and in no controls. These data clearly demonstrate impaired cardiac conductivity, developing concurrently with dilated cardiomyopathy, with loss of CENP-F function. This is probably a consequence of the reduced integrity of the intercalated discs, either as a direct result of disrupted CENP-F-mediated trafficking of connexin proteins to the intercalated disc, or as a secondary phenomenon to intercalated disc deterioration and fibrosis.

*CENP-F^−/−^* hearts are fibrotic and enlarged in adult mice
------------------------------------------------------------

Gross anatomical examination revealed a progressive dilation of *CENP-F^−/−^* hearts in comparison with WT hearts. Echo data from these mice at 1 year of age are shown in supplementary material [Fig. S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1) and demonstrate depressed left ventricular function. Masson's trichrome staining demonstrated fibrosis throughout the *CENP-F^−/−^* heart ([Fig. 7](#f7-0050468){ref-type="fig"}). This fibrosis was often continuous with the epicardium and these areas could be seen in whole-mount as nodules on the surface of the *CENP-F^−/−^* heart ([Fig. 7G](#f7-0050468){ref-type="fig"}). Additionally, there were fewer myocytes in *CENP-F^−/−^* hearts compared with WT hearts, as determined by quantification of myosin-positive cells by immunostaining (supplementary material [Fig. S5](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1)). This probably reflects lower myocyte numbers from the newborn period, with additional losses related to fibrosis. During longitudinal follow-up over a 9-month period of analysis, the experimental animal population had a 20% mortality rate, with no death of WT animals. These deaths were sudden with no sentinel symptoms of illness. Thus, disruption of CENP-F in cardiomyocytes leads to fibrosis, arrhythmia, and progressive ventricular dilation and dysfunction -- a phenotype with all the hallmarks of dilated cardiomyopathy.

Transcriptional profiling reveals both expected and novel patterns for dilated cardiomyopathy
---------------------------------------------------------------------------------------------

To obtain a broad perspective on differences between *CENP-F^−/−^*and WT hearts, we performed microarray analysis on hearts from 1-year-old mice. Principal component analyses of these datasets confirmed minimal variability between the experimental replicates, with complete segregation between *CENP-F^−/−^* and WT hearts ([Fig. 8A](#f8-0050468){ref-type="fig"}). *CENP-F^−/−^* and WT hearts exhibited differential expression of 528 probes, of which 192 were upregulated and 336 were downregulated in *CENP-F^−/−^* hearts ([Fig. 8B](#f8-0050468){ref-type="fig"}). The 528 probes represented a total of 251 genes, 101 of which were upregulated and 150 downregulated in *CENP-F^−/−^* hearts. Of the total number of genes, 123 matched at least one other published report on altered gene expression in dilated cardiomyopathy in humans or in animal models ([@b4-0050468]; [@b37-0050468]; [@b41-0050468]; [@b45-0050468]; [@b11-0050468]; [@b56-0050468]). This is shown in the heat map in [Fig. 8C](#f8-0050468){ref-type="fig"} and in supplementary material [Table S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1). Importantly, *CENP-F* is among the genes reported to be downregulated in human end-stage dilated cardiomyopathy, corroborating our model of cardiomyopathy in *CENP-F^−/−^* hearts. These data also demonstrate that our mouse model of cardiomyopathy recapitulates many of the genetic alterations described in dilated cardiomyopathies of other causes. To look for novel patterns of gene expression, we performed analyses using the Partek, DAVID and GSEA databases. Signaling pathways that emerged from these analyses included MAPK signaling (ten genes; *P*=0.012) and ubiquitin-mediated proteolysis (six genes; *P*=0.042). Transcription factor pathways with significant representation among our data included C/EBP delta (seven genes; *P*=1.01×10^−2^) and serum response factor (SRF; seven genes *P*=1.95×10^−2^). Interestingly, one of the SRF-related genes was *Mir133a-1*, a microRNA that was downregulated in *CENP-F^−/−^* hearts and has been shown to increase arrhythmogenesis in congestive heart failure ([@b5-0050468]). Given the arrhythmias demonstrated in mice with *CENP-F^−/−^* hearts, we looked for ion channel genes that were altered. No overt alteration of sodium channel gene expression was identified to directly explain the arrhythmias observed in KO mice. Several channel-related genes were altered, however. Ahnak2 is linked to L-type calcium channels and localizes to the Z band of murine cardiomyocytes ([@b31-0050468]). Two isoforms of a potassium-channel-interacting protein were altered in *CENP-F^−/−^* hearts, one upregulated (Kcnip1) and one downregulated (Kcnip4). These related but distinct proteins have been shown to affect trafficking of the Kv4 potassium channel to the cardiomyocyte membrane, and seem to be major determinants of potassium channel stability ([@b69-0050468]). Finally, multiple probes (26) demonstrated downregulation of intronic sequences in the *Dlg1* gene, encoding synapse-associated protein (SAP)97, which is involved in targeting and anchoring various cardiac ion channels to the plasma membrane. Channels regulated by SAP97 include Kv4 potassium channels, discussed above ([@b15-0050468]), and cardiac sodium channels, where it targets channels to the intercalated disc rather than to lateral membranes ([@b53-0050468]). Taken together, transcriptional profiling analysis in conjunction with our structural and physiological studies established that loss of CENP-F function results in dilated cardiomyopathy.

![**MT network and costamere structure is abnormal in** ***CENP-F****^−/−^* **hearts.** (A--D) Low-power views of MTs (green) in cross-section from 12-month-old WT (A,B) and *CENP-F^−/−^* (C,D) hearts. (B,D) Merged images of MTs (green), actin (red) and TOPRO (blue). (E--G) Serial confocal sections (0.38 μm) of a WT MT network (green) at high power. (H) Composite reconstruction of three successive confocal slices showing MTs (green), actin (red) and TOPRO (blue) in a WT heart. (I--K) Serial confocal sections (0.38 μm) of a *CENP-F^−/−^* MT network (green) at high power. (L) Composite reconstruction of three successive confocal slices showing MTs (green), actin (red) and TOPRO (blue) in a *CENP-F^−/−^* heart. Scale bars: 10 μm.](DMM008680F5){#f5-0050468}

DISCUSSION
==========

CENP-F is a very large multifunctional protein that has roles in divergent cell properties, including proliferation, protein trafficking and regulation of the cytoskeleton ([@b84-0050468]; [@b2-0050468]; [@b8-0050468]; [@b13-0050468]; [@b47-0050468]; [@b75-0050468]; [@b17-0050468]; [@b16-0050468]; [@b55-0050468]; [@b36-0050468]). Until now, CENP-F loss of function has only been studied in vitro using knockdown or dominant-negative technologies. Here, for the first time, we analyze loss of gene function in vivo and find that CENP-F, through its interaction with the MT network, plays a crucial role in heart development as well as in adult cardiac function. Importantly, this study is the first to link disruption of MT-associated function with the development of dilated cardiomyopathy, thereby identifying a novel disease mechanism. Finally, this study has broad implications for development and disease because CENP-F loss of function is likely to impact a diverse array of cell-specific activities.

MT functions in the heart
-------------------------

Thus far, the majority of cytoskeletal research in the heart has focused on the actin network. However, the MT network also plays a crucial role in heart maintenance and function. For example, MT-binding protein EB1 has recently been shown to mediate trafficking of Cx43, an essential component of the intercalated disc, to the plasma membrane ([@b72-0050468]). Additionally, several studies in multiple animal models have observed an increase in MT network density during pressure overload induced by aortic banding ([@b12-0050468]; [@b28-0050468]; [@b77-0050468]; [@b82-0050468]; [@b30-0050468]). A functional disturbance similar to pressure overload can be replicated by application of MT stabilizers such as Taxol ([@b59-0050468]; [@b76-0050468]; [@b46-0050468]; [@b78-0050468]). Conversely, MT depolymerization improves contractile function in pressure overload hypertrophy ([@b25-0050468]). These results suggest a major role for the MT network in cytoskeletal plasticity as the heart transitions from a state of hypertrophy to failure ([@b82-0050468]; [@b83-0050468]). MTs are also implicated in the pathogenesis of arrhythmias associated with cardiac hypertrophy, although the mechanisms behind this are not clear ([@b50-0050468]; [@b83-0050468]).

Recent reviews of cardiac disease have identified classes of genes, with those of the actin cytoskeleton being most prominent among them, whose dysfunction leads to dilated cardiomyopathy ([@b68-0050468]; [@b23-0050468]; [@b58-0050468]; [@b40-0050468]). Although it is clear that the MT network impacts both development and function of the heart, direct linkage of any MT-network-associated gene product to cardiac disease had not yet been established ([@b14-0050468]). Here, we show that loss of an MT-binding protein, CENP-F, in the heart results in dilated cardiomyopathy. Our physiological, morphological and molecular data are consistent with established patterns for dilated cardiomyopathy. However, *CENP-F^−/−^* hearts have a unique combination of abnormalities, including reduced mitotic activity during embryogenesis, loss of intercalated disc structure and disruption of costameres, that underlie the phenotype of dilated cardiomyopathy. All of these abnormalities can be predicted from the functions of CENP-F that are manifested in cardiomyocytes. Finally, it is of interest to note that our review and analysis of human dilated cardiomyopathy microarrays revealed a significant decrease in CENP-F expression associated with the disease ([@b11-0050468]). Although this does not establish a causal effect from loss of CENP-F expression, the current data along with the established role of the MT network in cardiomyocytes would suggest that cardiomyopathies currently described as idiopathic would arise from disruption of this crucial and multifunctional cytoskeletal structure.

![**Mice with** ***CENP-F****^−/−^* **hearts develop dilated cardiomyopathy and dysrhythmias.** (A,B) M-mode ECG images from unanesthetized WT and *CENP-F^−/−^* mice, showing measurement of left ventricular internal dimension in diastole (LVIDd; red) and in systole (LVIDs; yellow). (C) Graph of LVIDd from WT (blue/circles) and *CENP-F^−/−^* (pink/squares) mice at ages as shown. *CENP-F^−/−^*mice show mild but progressive dilation over time, compared with WT. (D) Graph of cardiac function calculated as shortening fraction, or (LVIDd-LVIDs)/LVIDd, in WT (blue/circles) and *CENP-F^−/−^* (pink/squares) mice. *CENP-F^−/−^*mice show progressive functional impairment over time, compared with WT. (E,F) Examples of rhythm disturbances observed in *CENP-F^−/−^* mice. In E, there is a P wave ('j') that does not conduct, whereas the others do ('N'), representing an episode of second degree heart block. In F, there is slowing of the sinus rate with preserved AV conduction, representing sinus node dysfunction.](DMM008680F6){#f6-0050468}

![**Adult** ***CENP-F****^−/−^* **hearts are fibrotic and enlarged.** (A--F) Masson's trichrome stain of 12-month-old WT (A,C,E) and *CENP-F^−/−^* (B,D,F) hearts in cross-section. Low-power magnification shows coronary enlargement in *CENP-F^−/−^* mice (B) as compared with WT (A). High-power magnification reveals significant fibrosis (blue) in *CENP-F^−/−^* hearts (D,F) as compared with WT (C,E). (G,H) Two whole-mount views of WT and *CENP-F^−/−^* hearts. *CENP-F^−/−^* hearts have nodular surfaces (G; right) and are significantly enlarged compared with WT. Scale bars: 200 μm.](DMM008680F7){#f7-0050468}

CENP-F loss of function reduces mitotic activity
------------------------------------------------

Work from our group and others has demonstrated that CENP-F is important for the regulation of DNA synthesis and cell division ([@b2-0050468]; [@b8-0050468]; [@b13-0050468]; [@b17-0050468]; [@b16-0050468]). All of these studies showing a reduction but not elimination of cell proliferation are consistent with our current in vivo data. *CENP-F^−/−^* mice exhibit decreased cardiomyocyte proliferation in the embryo and during the first week of life, precisely paralleling the high-level expression pattern of CENP-F ([@b13-0050468]). The thinning of the myocardial wall in *CENP-F^−/−^* hearts is presumably the result of decreased myocyte proliferation and, in turn, renders the organ susceptible to dilation and disease. The decreased number of cardiomyocytes within the heart is likely to contribute to the development of dysfunction over time on the basis of a reduced 'reserve' of working cardiomyocytes.

![**Principal component analysis of signal values for 528 probes identified as significantly differential between 12-month-old** ***CENP-F****^−/−^* **and WT mouse hearts.** (A) The colors represent the different sample types (red: *CENP-F^−/−^* samples; blue: WT samples), and lines mark the centroids for each group. The *x*-axis, *y*-axis, and *z*-axis components represent 79.7%, 6.8% and 5.2%, respectively, of the total variability between experimental replicates. Ideally, experimental replicates cluster together and are apart from other samples, which was indeed the case. (B) Hierarchical clustering of 528 probes detected as significantly differential (at least 1.5-fold; *P*\<0.05) between *CENP-F^−/−^* and WT mouse hearts. Values shown are log base 2, and bright red, bright blue and gray indicate the highest, lowest and median normalized signal values, respectively. Vertical dendrograms represent the individual samples, of which there are three replicates for each sample type. *CENP-F^−/−^* samples are lanes 1--3 from the left and WT samples are lanes 4--6. 192 probes were significantly upregulated and 336 were significantly downregulated as compared with WT. (C) Heat map generated by hierarchical clustering of standardized fold-changes of 125 genes found as having differential expression in *CENP-F^−/−^* mice and also in dilated cardiomyopathy (DCM; in mouse or dog models of DCM and/or in human DCM). Color indicates relative levels of expression replicates, with bright red indicating upregulation and bright blue representing downregulation) in *CENP-F^−/−^* mice and DCM, relative to respective controls. Each row represents one gene, found as up- or downregulated in this study and also in DCM. Columns represent the three mouse *CENP-F^−/−^* replicates (compared with WT animal controls) and DCM. All genes shown were found to have statistically significant (*P*\<0.05; fold-change\>1.5) expression in our study and also in public repository data that were analyzed similarly to our data where possible (see supplementary material [Table S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.008680/-/DC1) for a list of genes).](DMM008680F8){#f8-0050468}

CENP-F loss of function disrupts intercalated discs
---------------------------------------------------

Differentiated *CENP-F^−/−^* myocytes also have decreased and clearly abnormal intercalated discs. The intercalated disc is a complex, cardiac-specific structure that regulates cell-cell communication and force transduction between myocytes, and is functionally analogous to cell-cell junctions in epithelia ([@b52-0050468]; [@b19-0050468]). Targeted deletion of the non-receptor protein tyrosine kinase focal adhesion kinase (FAK), a principal component of the costamere, causes dilated cardiomyopathy in mice and abnormal patterns of hypertrophy in response to stress ([@b51-0050468]; [@b10-0050468]). Interestingly CENP-F, although not a component of the disc, is essential for the maintenance of its structure and function, because transmembrane proteins, including N-cadherin, Bves and connexin-43, were significantly decreased at the disc in *CENP-F^−/−^* myocytes when compared with WT myocytes. Our previous work has shown that intracellular trafficking of integral membrane proteins to the cell surface is dependent on CENP-F. CENP-F interacts with SNAPs and syntaxins of the SNARE complex and provides a physical link between this trafficking machinery and the MT network ([@b54-0050468]; [@b55-0050468]). In particular, we demonstrated that connexin-43 translocation to the cell surface is regulated by CENP-F ([@b55-0050468]). The reduction of N-cadherin, Bves and connexin-43 is of particular interest because these three proteins have diverse functions at the disc in the regulation of force and electrical transduction. The loss of an MT-binding protein represents a mechanism underlying disruption of disc structure and/or function. Even though CENP-F is not a disc component, its loss clearly demonstrates a previously unknown mechanism for dilated cardiomyopathy, "a disease of the intercalated disc" ([@b52-0050468]).

CENP-F loss of function disrupts costamere structure
----------------------------------------------------

Given previous work on the regulation of the MT network by CENP-F, disruption or loss of costamere structure are also consistent with loss of CENP-F function in cardiomyocytes. The costamere is a crucial component of the force transduction machinery within cardiomyocytes ([@b49-0050468]; [@b1-0050468]). Juxtaposed between the sarcolemma and the myofibril, this structure is essential for the efficient transmission of force from the myofibril to the sarcolemma to the connective tissue environment ([@b63-0050468]). Structure of the MT network in *CENP-F^−/−^* cardiomyocytes is clearly altered, with the pattern of costamere-associated MTs being completely absent in these cells and an overall reduction in the amount of tubulin. The loss of costamere structure has been implicated in the loss of contractile function, a hallmark of *CENP-F^−/−^* hearts. Several costameric proteins are implicated in human dilated cardiomyopathy, including vinculin ([@b44-0050468]), sarcoglycan ([@b81-0050468]) and dystrophin ([@b38-0050468]; [@b80-0050468]; [@b39-0050468]). Dystrophin-associated cardiomyopathy is the most common of these, in association with the X-linked disease Duchenne's muscular dystrophy. Duchenne's muscular dystrophy is characterized by progressive skeletal muscle weakness in early childhood, and with the development of slowly progressing dilated cardiomyopathy usually beginning in the teenage years ([@b80-0050468]; [@b18-0050468]). Importantly, the Duchenne cardiomyopathy is also associated with diffuse and progressive cardiac conduction abnormalities ([@b64-0050468]). The pathology of these hearts is characterized by thinning of the ventricular wall with fibrosis and scarring within the epimyocardium, a setting remarkably similar to what we observe in the *CENP-F^−/−^* end-stage heart.

Delayed onset of cardiomyopathy
-------------------------------

Loss of CENP-F function in vivo results in a thin-walled heart, fewer intercalated discs and disruption of costamere-associated MTs. It is of interest to note that any one of these variations in cardiac structure could give rise to dilated cardiomyopathy. Thus, the dilated cardiomyopathy that we observe in *CENP-F^−/−^* mice is probably multifactorial in nature, even with the loss of only a single gene. We would note that the present study, although revealing the fundamental importance of CENP-F in organogenesis and adult heart function, does not determine whether adult onset of this cardiomyopathy is a disease of embryonic, neonatal or adult origin. Indeed, our data suggest that an embryonic 'hit' produces a structurally normal heart with fewer myocyte numbers and thinner walls. It is probable that ongoing stress in the mature heart, due to MT instability or dysfunction, then culminates in dilated cardiomyopathy. This is similar to the cardiomyopathy that develops in Duchenne's muscular dystrophy and many other causes of cardiomyopathies: a single gene defect present from the time of cardiogenesis results in dilated cardiomyopathy many years later. With information from this first in vivo analysis of *CENP-F* gene ablation, it is now possible to initiate loss of function at specific times in development and in adult life in an effort to pinpoint specific CENP-F functions that are essential for organ development and function, and whose absence leads to disease. Loss of CENP-F function leads to specific and, in retrospect, predictable changes in myocyte structure that suggest a generalized disruption of MT-network-associated activities within the cell. It will be important to determine whether other MT-associated proteins underlie developmental and disease states of the heart.

METHODS
=======

Developing the *CENP-F^−/−^* mouse
----------------------------------

BAC clones were used to analyze the 5′ region of the *CENP-F* gene and clone the gene segment into the pFRT-*loxP* vector (a gift from Mark Magnuson, Vanderbilt University, TN). This vector contains the *loxP* sites, the thymidine kinase negative-selection marker utilized for random vector integration events, and FRT sites used to delete the neomycin resistance cassette. This cloning strategy successfully isolated the first five exons of *CENP-F*, flanked by *loxP* sites. This targeting construct was electroporated into ES cells and resulting clones screened for recombination at the *CENP-F* locus. Two ES clones were positive for all sections of the screened locus, and were injected into blastocysts and placed in foster mothers. Founder pups were chosen by successful transmission in the germline, and progeny were backcrossed to the ICR background and maintained in this manner (Ryan D. Pooley, The role of LEK1 in recycling endosome trafficking and its function in heart development, PhD thesis, Vanderbilt University, [@b54-0050468]). We then crossed the *CENP-F^loxP/loxP^* mouse with cTNT-Cre mouse (a generous gift from Scott Baldwin, Vanderbilt University, TN) to target *CENP-F* deletion specifically in cardiomyocytes starting at embryonic day (E)7.5. All procedures involving experimental animals were performed in compliance with the Vanderbilt University Institutional Animal Care and Use Committee guidelines.

Genotyping
----------

PCR genotyping was based on three features to distinguish WT CENP-F from Cre-mediated CENP-F exon 1--5 deletion: presence of the 5′ *loxP* site upstream of *CENP-F*, generation of a DNA band only being possible with recombination after Cre-mediated excision, and the presence of the *cTNT-Cre* gene. The primers used were: Across 5′ *loxP* site: 5′-AATAATGAAGCTGACACCAAAAACT-3′, 3′-GAACCTACCGTCTGAGAACCACTG-5′; Recombination band: 5′-AATAATGAAGCTGACACCAAAAACT-3′, 3′-GAGGAGCACAGGAGGGAAATG-5′; cTNT-Cre: 5′-TCCGGGCTGCCACGACCAA-3′, 3′-GGCGCGGCAACACCATTTTT-5′.

Organ and tissue preparation for histochemical analysis
-------------------------------------------------------

Mouse hearts, both embryonic and adult, were isolated from the animal, imaged on a Zeiss Stemi 2000-C stereomicroscope with an Olympus camera (model no. 60806; Optronics) for gross anatomical analysis, fixed with methanol, and washed in PBS prior to placement in OCT compound (Sakura) and freezing. Frozen tissues were cryosectioned at a thickness of 7 μm. Successive sections were collected on glass slides and stored at −20°C until immunohistochemical analysis. Frozen tissues slides were processed as previously described ([@b3-0050468]; [@b13-0050468]). Histological stains were visualized by fluorescence microscopy on an AX70 (Olympus) and digital images were captured and processed using Magnafire (Optronics) and Photoshop (Adobe) software. CENP-F labeling was conducted with a polyclonal antibody (Spec1) to CENP-F peptide ([@b75-0050468]). Other antibodies include anti-phosphohistone-H3 (Millipore), rabbit polyclonal to N-cadherin (Abcam), DM1A (Abcam), MF20 (DSHB) and Alexa-Fluor-568--phalloidin (Invitrogen), and were used as previously described ([@b3-0050468]) or as per the manufacturer's instructions. DAPI (Boehringer Mannheim) and TO-PRO-3 iodide (Invitrogen) were used to visualize nucleic material. Histological analysis with hematoxylin and eosin (H&E) and Masson's trichrome staining was standard. E15.5 WT and *CENP-F^−/−^* heart sections were stained with DAPI and anti-PH3 antibodies. PH3-positive nuclei were quantified from 25 different fields of view (20× magnification) from multiple sections. For BrdU labeling, neonatal mice were subcutaneously injected with 0.1 ml BrdU labeling reagent per 100 g of body weight as per the manufacturer's instructions (Roche). After 90 minutes the animals were sacrificed, and heart tissue processed and sectioned as above. Tissue fixation, and anti-BrdU primary and secondary antibody staining for this procedure were all performed using Roche reagents and protocols ([@b13-0050468]). In situ hybridization analyses of mouse embryos were conducted using published methods ([@b85-0050468]). Three prime coding and non-coding sequences (1.6 kb) of murine *CENP-F* were cloned into pGEM-T Easy, as described previously ([@b2-0050468]). Antisense and sense probes were generated using T7 and SP6 polymerases, respectively. Hybridization, washing and antibody detection of probes were standard. No reaction was detected with sense controls.

Quantification of intercalated discs
------------------------------------

Frozen heart sections were post-fixed in a 50:50 mixture of acetone and methanol for 10 minutes at −20°C. Sections were rehydrated and stained with monoclonal anti-connexin-43 (Sigma) and DAPI or TOPRO3 to stain the DNA. Secondary Alexa-Fluor-488 anti-mouse IgM antibodies (Invitrogen) were used to recognize connexin-43-enriched intercalated discs. Anti-Bves antiserum was also used to visualize intercalated discs ([@b70-0050468]). For quantification purposes, images were taken (Olympus Ax70 at 40× magnification) from 20 random fields of view on multiple sections and the number of discs present in each field was quantified. For standardization purposes, we identify a disc as a contiguous area positive for connexin-43 staining and greater than 5 μm in length. Representative confocal images were acquired on a Zeiss LSM 510 inverted microscope maintained by the Vanderbilt Cell Image Shared Resource Core. Quantification is shown as fold difference between WT and *CENP-F^−/−^* animals at 1 year of age.

Cardiomyocyte quantification
----------------------------

Frozen heart sections were stained with anti-MF20 and DAPI. MF20-positive cells were quantified from 30 different fields of view on multiple sections (20× magnification) for WT and *CENP-F^−/−^*hearts at 1 year of age.

Echocardiography
----------------

Imaging was performed using a Hewlett-Packard Sonos 5500 or a VisualSonics Vevo 2100 system, with a 12 MHz transducer in unanesthetized mice held in a left lateral decubitus position. Mice were imaged in a parasternal long axis view to study the septum, posterior wall, apex and left ventricular outflow tract, and in a short axis view at the chordal level to study symmetry of wall thickness and contraction ([@b62-0050468]). From these studies, M-mode images were recorded on a strip chart at a speed of 100 mm/second. Dimensions from the M-mode tracings and the summary interpretation were entered in the database after review of the data quality, raw data and interpretation by a trained echocardiographer. This work was performed in the Vanderbilt University Murine Cardiovascular Core.

###### TRANSLATIONAL IMPACT

**Clinical issue**

Cardiomyopathies are diseases of the myocardium and can often be classified as hypertrophic, restrictive or dilated. Progress has been made in identifying the genetic basis of these life-threatening diseases, particularly of hypertrophic cardiomyopathy. Although genes that can cause either hypertrophic or dilated cardiomyopathy (depending on the mutation) have been identified, most cases of dilated cardiomyopathy remain idiopathic in terms of their genetic origin. Undoubtedly, some genetic defects that cause dilated cardiomyopathy involve proteins not yet clinically associated with this disease. Without a more complete understanding of the origin of this disease and how it disrupts heart structure and function, the design of new therapies will be limited.

**Results**

The authors characterized an in vivo cardiomyocyte-specific knockout of CENP-F, a large microtubule-associated protein with multiple functions, including the regulation of cell shape, mitosis and subcellular vesicles trafficking. At the onset of heart development, *CENP-F^−/−^* hearts were smaller, exhibited decreased myocyte proliferation and had thinner walls than age-matched controls. These hearts also contained fewer intercalated discs (the myocyte-specific junctional complexes responsible for electrical and force transduction), and costameres (the myocyte-specific cytoskeletal link between myofibrils and the cell membrane) were severely disrupted. Impairment of both the intercalated disc and the costamere has been associated with cardiomyopathy; this study demonstrates that CENP-F is crucial for establishment and/or maintenance of these structures. Over 12 months, *CENP-F^−/−^* hearts became enlarged, fibrotic and developed arrhythmias, all of which are hallmarks of disease associated with progressive dilated cardiomyopathy. Furthermore, transcriptional profiling of *CENP-F^−/−^* hearts revealed findings that are in line with previous reports of dilated cardiomyopathy in model organisms and humans.

**Implications and future directions**

These findings represent an advance in the analysis of heart disease, and reveal a new disease mechanism involving disruption of a particular gene product, and more broadly of the microtubule network. This is also the first report of an in vivo knockout of CENP-F and the first reported genetic link between disruption of a microtubule-associated protein and heart disease. The complexity and diversity of microtubule components suggests that a proportion of dilated cardiomyopathies might be caused by mutations in the many genes that encode several other microtubule-associated proteins. Future investigation of this issue might provide insight into other forms of heart disease and dysfunction.

Electrocardiography
-------------------

Small (\<4 gm) telemetry devices (Data Sciences) were implanted under anesthesia in the peritoneum and the wires tunneled to the left shoulder and right leg of WT and *CENP-F^−/−^* animals. Recovery occurred within a day and, via a telemetry receiver placed under the cage, ECG data were obtained for at least 30 minutes per animal in unanesthetized, unrestrained animals. A total of 48 hours of recordings were obtained and scanned for RR intervals greater than 200 ms. An electrophysiologist examined all data (raw and analyzed) and insured quality control. This work was performed in the Vanderbilt University Murine Cardiovascular Core.

Microarray analysis
-------------------

RNA samples were obtained from WT and KO mouse hearts, labeled and hybridized to Affymetrix Mouse Gene 1.1 ST arrays, yielding a total of 12 arrays (four groups; *n*=3). Microarray images were scanned with an Affymetrix high resolution GenePix 4000B scanner in the Vanderbilt Functional Shared Resource (<http://www.thefgsr.com/>). Data was uploaded into Partek Genomics Suite version 6.6 (Partek Incorporated, St Louis, MO) and processed using Robust Multi-chip Average (RMA) normalization ([@b7-0050468]; [@b24-0050468]; [@b29-0050468]; [@b26-0050468]). The normalization procedures successfully resulted in comparable hybridization signals across the entire array set, and histograms, M versus A plots and scatter plots (data not shown) demonstrated comparable hybridization signals across replicate samples. Using Partek, pairwise comparisons of average group values and one-way ANOVA for analysis of WT versus KO heart were performed. Only probes that resulted in a fold change of at least 1.5 and *P*-value of less than 0.05, with or without Benjamini and Hochberg multiple hypothesis correction ([@b27-0050468]), were considered as significantly altered. Individual pairwise comparisons were also performed to ascertain the level of consistency and to identify the top altered genes for each major comparison. Gene functions were determined using publicly available records using NCBI Entrez Gene, Stanford SOURCE, Aceview and PubMed databases. Sequences for differential probes not associated with transcripts, based on Affymetrix database annotations, were retrieved from the Affymetrix NetAffx Analysis Center website (<http://www.affymetrix.com/analysis/index.affx>) and searched in the UCSC Genome Browser (<http://genome.ucsc.edu/>) using BLAT ([@b6-0050468]). Statistical analyses (including correction for multiple hypothesis testing) for identification of overrepresented ontologies, functions and pathways were performed using DAVID (<http://david.abcc.ncifcrf.gov>) and the Partek Genomics Suite.
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